ENDIA

New Australian research highlights the benefits of continuous glucose monitoring ( ) during pregnancy for women living with type 1 diabetes.

Here we report on the first population-based Australian study of its kind, including the contribution of a significant number of mothers participating in the ENDIA Study. Researchers found women using CGM experienced greater improvements in blood glucose control during pregnancy compared with those not using CGM.

These findings closely matched results from previous international clinical trials (e.g. CONCEPTT), showing CGM can help support glucose levels throughout pregnancy.

The study also reinforced the importance of glucose management before conception, as early pregnancy HbA1c was the strongest predictor of glucose outcomes later in pregnancy.

While CGM improved glycaemic management, challenges remain. Rates of babies being born larger than expected and neonatal complications were still higher when compared to the general population. This highlights the need for continued research and support for families affected by type 1 diabetes.

These real-world findings provide reassuring evidence that CGM is an important tool for diabetes management during and supporting optimal outcomes for mothers and babies.

Read more at: https://doi.org/10.1177/15209156261455567

And BIG thanks to Jess for sending us this beautiful photo of her pregnancy

Superhero sisters, Audra and Eden, have hung up their capes and completed their final study visit with the ENDIA Team. Their family have been huge supporters of our research and of their children participating fully.

We’re incredibly grateful and will miss them all so much. We are sure you will pick up your superhero capes again and again as you grow into amazing young humans in whatever you choose to do in the future, girls.

Thank you. Fly well.

🦸‍♀️🦸‍♂️

Congratulations to Clara on graduating from the ENDIA Study!
From her very first visit to her last, Clara (and her family!) have been an incredible part of our research community. Every visit, every sample, every moment of patience adds up — and helps us understand more about how and why type 1 diabetes develops in children, so that one day we can prevent it.
Thank you, Clara. You're a superstar. ⭐

We're nearing the end of recruitment to interview families with experience of coeliac antibodies detected via screening.

If you or your child have screened for coeliac disease and found to have antibodies, or diagnosed with after screening, we'd really appreciate talking to you.

Interviews take around 30 minutes, can be conducted out of hours and a voucher will be sent to reimburse your time.

For more information or a no obligation chat, email [email protected] or click this link: https://adelaideuniwide.qualtrics.com/jfe/form/SV_ai1gunhvweaEHjg

As screening and monitoring programs roll out across the globe, it's important to hear from people with lived experience to inform best models of care.

25 Years of Progress: Pregnancy with Type 1 Diabetes

A Danish study of 1.5m pregnancies (1997-2021) found maternal outcomes for those living with improved significantly:

• 38% fewer preterm births
• 38% fewer very preterm births
• 27% fewer extremely large babies

Although risks remain higher when compared with women from the general population, progress is real. Pregnancy outcomes for those where the father had diabetes were comparable to the general population.

Glucose management during , and less so genetics, remains important in antenatal care.

Read more at https://doi.org/10.1111/1471-0528.70174

This dynamic duo, Hazel and Maya, have been helping ENDIA since they were babies! And now here they are in primary school and growing up into two terrific gals.

Double samples, double contributions with special thanks to mum for helping to collect them all and bring the girls to see nurse Rose.

Thanks so much ladies for all your valuable help to find the cause/s of We couldn't do it without you.

A big thank you to two incredible siblings who have just reached a major milestone — completing their final visits.

Eldest brother, Harrison, turned 10 this year! Happy birthday, Harrison. Together with his 7-year-old sister, Darcie, he has grown up as part of our research family. Their participation, and the commitment of their over many years, has contributed real and lasting value to our understanding of .

Longitudinal research like ENDIA depends on families who give their time and trust, year after year. We are deeply grateful. Thank you to these 🦸‍♀️🦸‍♂️

💙

Association of fever and infections and subsequent risk of atopic diseases in children at risk for type 1 diabetes: Results from the TEDDY cohort study.

Atopic diseases are a group of common conditions where the immune system overreacts to normal things in the environment. They are strongly linked by genetics and often run in families.

A large international study (TEDDY) found acts as a double-edged sword for childhood allergies.

While getting a fever during a tends to increase the risk of developing asthma, fevers (especially with no other symptoms) seem to protect children from developing eczema or hay fever later on.

Fevers without other severe cold or flu symptoms appear to have the opposite effect. They act as a "shield," lowering the risk of developing atopic eczema and allergic rhinitis (hay fever).

This research indicates fever plays a major role in how the body reacts to infections and develops allergies.

These insights could help doctors and researchers design better preventive strategies to protect children from allergy-related conditions in the future.

Read more online at https://doi.org/10.1111/pai.70209

A very special shout out to 9-year-old Zidan who has completed his final ENDIA study visit.

From the very beginning of his life, he and his family have given their time, their data, their samples, and their commitment to help us understand development. This contribution is embedded into the research in ways that will matter for families for years to come.

To Zidan and his family — thank you. We hope you know that being part of something this important, for this long, is something truly worth being proud of. These years of participation are a gift to every family affected by type 1 diabetes.

Here's to you, Zidan. Wishing you all the very best for the future.

The Australian Therapeutic Goods Administration (TGA) has approved Tzield (teplizumab) to delay the onset of stage 3 (symptomatic) .

Stage 2 means two or more islet autoantibodies (early markers) have been detected from a blood test and glucose levels are erratic ( ), but no symptoms are evident.

The progression of type 1 diabetes happens in stages. People with stage 2 T1D will gradually progress to stage 3 T1D, with the experience of symptoms ( , , and losing weight, more often). Elevated glucose levels require insulin treatment. This process can take place over months or years.

Studies of Tzield have proven to slow this progression by an average of 2 years. That's at least two years less of injections and finger pricks.

This is the first new therapy approved for T1D in over 100 years, since the discovery of .

Tzield involves an intravenous (IV) infusion. People must be aged 8 years or older and in stage 2 type 1 diabetes.

Read more on the Breakthrough T1D Australia website:

https://breakthrought1d.org.au/news/tzield-approved-in-australia/